Platinum
Immunomedics, a subsidiary of Gilead Sciences
- FLASCO
- September 25, 2020
- No Comments
Immunomedics, a subsidiary of Gilead Sciences, is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping people with hard-to-treat cancers. For more information, visit: www.immunomedics.com. TRODELVY ACCESS SERVICES is a patient access and reimbursement support program. It will help you understand specific coverage and reimbursement guidelines for TRODELVY® (sacituzumab govitecan-hziy) 180mg single-dose vial. For full Prescribing…
Karyopharm Therapeutics
- FLASCO
- April 10, 2020
- No Comments
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the…
Daiichi Sankyo, Inc.
- FLASCO
- March 19, 2020
- No Comments
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its…
Natera
- Katrina Williams
- September 4, 2019
- No Comments
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types…
Coherus Biosciences
- Katrina Williams
- February 6, 2019
- No Comments
Coherus is led by a team of biotech industry pioneers focused on disrupting the status-quo and driving tangible change in healthcare. Many of our leaders were directly involved in developing, manufacturing, and commercializing blockbuster biologics that elevated biologics from niche to mainstream medicine. Today, the team is unlocking the true potential of this category and…
EMD Serono
- FLASCO
- March 22, 2017
- No Comments
EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany – a leading science and technology company – in the U.S. and Canada, focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in…
Exelixis, Inc.
- FLASCO
- June 7, 2016
- No Comments
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.
Pharmacyclics
- FLASCO
- July 16, 2015
- No Comments
Every day, too many people miss out on the beauty and richness of life: A morning cup of coffee, reading to a grandchild, noticing a neighbor’s garden while out for a walk. These are treasures when someone has the strength, vitality, and opportunity to enjoy them. However, to a person dealing with life-threatening illness, opportunities…
Novartis
- FLASCO
- July 16, 2015
- No Comments
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products…
Sandoz, a Novartis Division
- FLASCO
- July 16, 2015
- No Comments
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. With our leading-edge processes in manufacturing, strong pipeline of treatments and reliable supply, we strive to improve patient access to more affordable,…
Taiho Oncology
- April 26, 2015
- No Comments
Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the…
Teva Pharmaceuticals
- FLASCO
- February 11, 2015
- No Comments
Company Overview Patient Assistance Programs Overview People are at the heart of what drives Teva Oncology. As a top 10 oncology company in the US, we strive to improve the lives of people affected by cancer. Our focus is to provide solutions in hematologic malignancies, solid tumors and supportive care. At Teva Oncology, our vision…
Lilly Oncology
- November 20, 2014
- No Comments
There’s a time when everything changes. That life-altering moment when someone hears, “You have cancer.” That moment is what motivates everyone at Lilly Oncology. Patient TruAssist Program PatientOne Assistance Program
